GlassScriptPhysician profile
Hao Huang
NPI 1316490378
$5,329.83
in general payments reported to CMS, 2019-2025
31 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $919 · 2023: $1,516 · 2024: $1,370 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.60 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $563.05 | 2021-2024 | Ajovy, Austedo Xr |
| Polynovo North America LLC | $510.98 | 2024-2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $461.13 | 2022-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Davol INC. | $456.58 | 2024-2025 | Phasix Mesh |
| Lundbeck LLC | $337.31 | 2022-2025 | Vyepti |
| Biogen, INC. | $273.14 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $272.59 | 2021-2024 | Emgality, Reyvow |
| Celgene Corporation | $261.68 | 2023-2025 | Zeposia |
| Pfizer INC. | $185.16 | 2023-2024 | |
| Kerecis Limited | $149.87 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Rti Surgical, INC | $135.83 | 2025 | |
| Avita Medical Americas, LLC | $107.97 | 2023 | Recell |
| Kci USA, INC. | $102.92 | 2023 | Prevena, V.A.C. Veraflo |
| Biohaven Pharmaceutical Holding Company LTD. | $87.66 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.91 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $47.26 | 2022-2023 | Ultomiris, Soliris |
| Springworks Therapeutics, INC. | $38.39 | 2025 | Gomekli |
| Allergan, INC. | $28.41 | 2022 | |
| Neuropace, INC. | $25.31 | 2024 | |
| Sk Life Science, INC. | $23.69 | 2023 | |
| Philips North America LLC | $20.88 | 2024 | (Ak6) Vest Therapy |
| Axonics, INC. | $18.70 | 2024 | Axonics, Bulkamid |
| Merz Pharmaceuticals, LLC | $18.61 | 2024 | Xeomin |
| Biohaven Pharmaceuticals, INC. | $17.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.00 | 2024 | Andexxa |
| Jazz Pharmaceuticals INC. | $17.00 | 2023 | |
| Scilex Pharmaceuticals INC. | $16.95 | 2024 | |
| Genzyme Corporation | $16.09 | 2023 | |
| Livanova USA, INC. | $14.90 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals LLC | $2.18 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hao Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.